{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T02:58:50Z","timestamp":1782183530373,"version":"3.54.5"},"reference-count":47,"publisher":"Informa UK Limited","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Opinion on Drug Safety"],"published-print":{"date-parts":[[2005,1]]},"DOI":"10.1517\/14740338.4.1.69","type":"journal-article","created":{"date-parts":[[2005,5,4]],"date-time":"2005-05-04T12:26:17Z","timestamp":1115209577000},"page":"69-73","source":"Crossref","is-referenced-by-count":55,"title":["Tolcapone in Parkinson\u2019s disease: liver toxicity and clinical efficacy"],"prefix":"10.1517","volume":"4","author":[{"given":"Nuno","family":"Borges","sequence":"first","affiliation":[{"name":"University of Porto, Faculty of Nutrition and Food Sciences, Rua Dr Roberto Frias, 4200-465 Porto, Portugal. nunoborges@fcna.up.pt"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2005,4,22]]},"reference":[{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.51.2_Suppl_2.S2"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-4886(03)00304-2"},{"key":"e_1_2_1_7_1","unstructured":"\u2022\u2022Thorough review of PD treatment."},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6446(97)01158-6"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.50.5_Suppl_5.S3"},{"key":"e_1_2_1_10_1","doi-asserted-by":"crossref","unstructured":"LEWITT PA: New drugs for the treatment of Parkinson's disease. Pharmacotherapy (2000) 20:26S\u201332S.","DOI":"10.1592\/phco.20.2.26S.34631"},{"key":"e_1_2_1_11_1","first-page":"741","article-title":"[Modern therapeutic possibilities in Parkinson's disease]","volume":"129","author":"LUDIN HP","year":"1999","unstructured":"LUDIN HP: [Modern therapeutic possibilities in Parkinson's disease]. Schweiz Med. Wochenschr. (1999) 129:741\u2013747.","journal-title":"Schweiz Med. Wochenschr."},{"key":"e_1_2_1_12_1","first-page":"291","article-title":"LUNDSTROM K et aL: Characteristics of catechol 0-methyl-transferase (COMT) and properties of selective COMT inhibitors","volume":"39","author":"MANNISTO PT","year":"1992","unstructured":"MANNISTO PT, ULMANEN I, LUNDSTROM K et aL: Characteristics of catechol 0-methyl-transferase (COMT) and properties of selective COMT inhibitors. Prog Drug Res. (1992) 39:291\u2013350.","journal-title":"Prog Drug Res"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)79311-9"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(99)00042-8"},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.32.8.887"},{"key":"e_1_2_1_16_1","first-page":"928","article-title":"Tolcapone added to levodopa in stable parkinsonian patients: a double- blind placebo-controlled study","volume":"12","author":"DUPONT E","year":"1997","unstructured":"DUPONT E, BURGUNDER JM, FINDLEY LJ, OLSSON JE, DORFLINGER E: Tolcapone added to levodopa in stable parkinsonian patients: a double- blind placebo-controlled study. Tolcapone in Parkinson's disease Study Group II (TIPS II). Mov. Disord. (1997) 12:928\u2013934.","journal-title":"Tolcapone in Parkinson's disease Study Group II (TIPS II). Mov. Disord."},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/0306-3623(94)90082-5"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200059060-00004"},{"key":"e_1_2_1_19_1","unstructured":"\u2022Important review on COMT inhibitors."},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.43.12.2685"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-199605060-00006"},{"key":"e_1_2_1_22_1","first-page":"665","article-title":"Tolcapone in stable Parkinson's disease: efficacy and safety of long- term treatment","volume":"49","author":"WATERS CH","year":"1997","unstructured":"WATERS CH, KURTH M, BAILEY P et al.: Tolcapone in stable Parkinson's disease: efficacy and safety of long- term treatment. The Tolcapone Stable Study Group. Neurology (1997) 49:665\u2013671.","journal-title":"The Tolcapone Stable Study Group. Neurology"},{"key":"e_1_2_1_23_1","first-page":"S123\u2013S123","article-title":"DURIF F: Effect of entacapone on quality of life in Parkinson's disease","volume":"49","author":"GORDIN A.","year":"2001","unstructured":"GORDIN A. REINIKAINEN K, DURIF F: Effect of entacapone on quality of life in Parkinson's disease. J. Am. Geriam. Soc. (2001) 49:S123\u2013S123.","journal-title":"J. Am. Geriam. Soc."},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1159\/000052104"},{"key":"e_1_2_1_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)61511-5"},{"key":"e_1_2_1_26_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1005549304404"},{"key":"e_1_2_1_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s004150050477"},{"key":"e_1_2_1_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.57.2.263"},{"key":"e_1_2_1_29_1","unstructured":"\u2022Detailed appraisal of tolcapone hepatotoxicity by a panel of experts."},{"key":"e_1_2_1_30_1","unstructured":"NO AUTHORS LISTED: European Medicine Evaluation Agency: Recommendation for the suspension of the marketing authorization for Tasmar\u00ae (tolcapone). Press Release (1998)"},{"key":"e_1_2_1_31_1","unstructured":"NO AUTHORS LISTED: European Medicine Evaluation Agency: EMEA Public statement on the lifting of the suspension of the marketing authorisation for tolcapone (Tasmar\u00ae). Press Release (2004)"},{"key":"e_1_2_1_32_1","unstructured":"ELLISON RH: Dear Healthcare Professional letter regarding appropriate use of Tasmar\u00ae. Roche Laboratories Inc. (1998)."},{"key":"e_1_2_1_33_1","unstructured":"NO AUTHORS LISTED: New warnings for Parkinson's drug Tasmar. Food and Drug Administration Talk Paper (1998)."},{"key":"e_1_2_1_34_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2.3.263"},{"key":"e_1_2_1_35_1","unstructured":"\u2022Recent and detailed review on tolcapone hepatotoxicty."},{"key":"e_1_2_1_36_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200326110-00001"},{"key":"e_1_2_1_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(97)01431-3"},{"key":"e_1_2_1_38_1","unstructured":"\u2022Seminal paper on the mechanisms of tolcapone toxicity."},{"key":"e_1_2_1_39_1","doi-asserted-by":"crossref","unstructured":"HAASIO K KOPONEN A. PENTTILA KE NISSINEN E: Effects of entacapone and tolcapone on mitochondrial membrane potential. Eur. J. Pharmacol. (2002) 453:21\u201326.","DOI":"10.1016\/S0014-2999(02)02383-X"},{"key":"e_1_2_1_40_1","doi-asserted-by":"publisher","DOI":"10.1078\/0940-2993-00228"},{"key":"e_1_2_1_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-002-0748-x"},{"key":"e_1_2_1_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2003.10.015"},{"key":"e_1_2_1_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s007020170099"},{"key":"e_1_2_1_44_1","doi-asserted-by":"publisher","DOI":"10.1021\/tx025569n"},{"key":"e_1_2_1_45_1","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0090-9556(25)07341-6","article-title":"OTTOILA P, TASKINEN J: Identification of major metabolites of the catechol-O-methyltransferase inhibitor entacapone in rats and humans","volume":"21","author":"WIKBERG T","year":"1993","unstructured":"WIKBERG T, VUORELA A. OTTOILA P, TASKINEN J: Identification of major metabolites of the catechol-O-methyltransferase inhibitor entacapone in rats and humans. Drug Metab. Dispos. (1993) 21:81\u201392.","journal-title":"Drug Metab. Dispos."},{"key":"e_1_2_1_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.tpj.6500123"},{"key":"e_1_2_1_47_1","unstructured":"\u2022\u2022Elegant approach to the problem of tolcapone hepatotoxicity."},{"key":"e_1_2_1_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10342"},{"key":"e_1_2_1_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10369"},{"key":"e_1_2_1_50_1","doi-asserted-by":"publisher","DOI":"10.1159\/000050749"},{"key":"e_1_2_1_51_1","unstructured":"SHEPHERD J CLEGG k Entacapone asan adjunctive treatment to levodopa in Parkinson's disease. Wessex Institute for Health Research and Development. Development and Evaluation Committee Report No. 104 (1999)."}],"container-title":["Expert Opinion on Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/14740338.4.1.69","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T02:00:35Z","timestamp":1772762435000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1517\/14740338.4.1.69"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,1]]}},"alternative-id":["10.1517\/14740338.4.1.69"],"URL":"https:\/\/doi.org\/10.1517\/14740338.4.1.69","relation":{},"ISSN":["1474-0338","1744-764X"],"issn-type":[{"value":"1474-0338","type":"print"},{"value":"1744-764X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,1]]}}}